Compare MLR & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLR | RZLT |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.9M | 470.9M |
| IPO Year | 2004 | 2011 |
| Metric | MLR | RZLT |
|---|---|---|
| Price | $49.03 | $4.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $48.50 | $9.67 |
| AVG Volume (30 Days) | 69.5K | ★ 2.2M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $790,271,000.00 | N/A |
| Revenue This Year | $10.63 | N/A |
| Revenue Next Year | $18.84 | N/A |
| P/E Ratio | $965.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.81 | $1.07 |
| 52 Week High | $52.93 | $11.46 |
| Indicator | MLR | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 57.21 |
| Support Level | $45.74 | $2.91 |
| Resistance Level | $49.35 | $5.42 |
| Average True Range (ATR) | 1.74 | 0.31 |
| MACD | -0.37 | -0.05 |
| Stochastic Oscillator | 36.19 | 23.94 |
Miller Industries Inc is a manufacturer of Towing and Recovery Equipment. The company designs and manufactures bodies of car carriers and wreckers, which are installed on chassis manufactured by third parties, and sold to customers. Its product lines include car carriers, light duty, heavy duty, rotators, special transport, military, wreckers, and transport trailers. It sells products under various brands including Century, Vulcan, Chevron, Holmes, Challenger, Champion, Jige, Boniface, Omars, Titan, and Eagle.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.